StreetInsider.com News Articles

UBS Reiterates Neutral Rating on Humana (HUM) as Guidance Reaffirmed

Mon, 15 Jun 2026 09:43:03 -0400

UBS analyst AJ Rice reiterated a Neutral rating and $320.00 price target on Humana (NYSE: HUM).

The analyst commented, "We had a chance to catch up with HUM (6/12) before the company enters its quiet period. With HUM issuing its normal reaffirmation of guidance on the start of the third month in the quarter, the company has seen utilization tracking in line to slightly better than expectation for new and continuing members. May data would not have been closed by June but an early look at the data would have been considered in the June reaffirmation. This quarter's guidance affirmation timing

UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald

Thu, 11 Jun 2026 07:16:52 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $440.00 price target on UnitedHealth Group (NYSE: UNH)..

The analyst commented, "Next Medicaid Catalysts: 1) TX Star Kids 137K enrollee / $4B LTSS CHIP contract award - incumbents are UNH, CNC, ELV, CVS & 4 private companies, 2) Protest resolution of TX STAR & CHIP 3.1M enrolled / $9.7B contract - winners are CVS, UNH, MOH, ELV, CNC & HUM, 3) Protest resolution of GA Families & Families 360 - winners are MOH, UNH & HUM."

For an analyst ratings summary and ratings history on UnitedHealth Group click here. For

UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald

Thu, 11 Jun 2026 07:16:52 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $440.00 price target on UnitedHealth Group (NYSE: UNH)..

For an analyst ratings summary and ratings history on UnitedHealth Group click here. For

UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald

Thu, 11 Jun 2026 07:16:52 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $440.00 price target on UnitedHealth Group (NYSE: UNH)..

For an analyst ratings summary and ratings history on UnitedHealth Group click here. For

UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald

Thu, 11 Jun 2026 07:16:52 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $440.00 price target on UnitedHealth Group (NYSE: UNH)..

For an analyst ratings summary and ratings history on UnitedHealth Group click here. For

UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald

Thu, 11 Jun 2026 07:16:52 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $440.00 price target on UnitedHealth Group (NYSE: UNH)..

For an analyst ratings summary and ratings history on UnitedHealth Group click here. For

UnitedHealth Group (UNH) Reiterate at Overweight by Cantor Fitzgerald

Thu, 11 Jun 2026 07:16:52 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $440.00 price target on UnitedHealth Group (NYSE: UNH)..

For an analyst ratings summary and ratings history on UnitedHealth Group click here. For

Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald on $30B RFP Medicaid Award

Thu, 11 Jun 2026 07:14:14 -0400

Cantor Fitzgerald analyst Sarah James reiterated a Neutral rating and $100.00 price target on Humana (NYSE: HUM).

The analyst commented, "IL announced its estimated $30B / 3.1M Medicaid Contract awards covering TANF / CHIP / LTSS - HUM is added as a new entrant & CNC / CVS / MOH maintained incumbency. The state expects the contract to start 1/1/27 and run for 4.5 years, with the option to extend up to an additional 5.5 years. This timeline is unchanged & aligned with commentary MOH included in its I-Day commentary. The contract scoring is composed of 450 points for technical requirements

Humana to sell minority stake in Gentiva for $900 million

Wed, 10 Jun 2026 16:30:27 -0400

Humana Inc. (NYSE: HUM) signed a definitive agreement to divest its minority interest in Gentiva to a consortium of investors for approximately $900 million, according to a company statement.

The transaction involves all or substantially all of Humana's minority stake in Gentiva, described as the nation's leading provider of end-of-life services, including hospice and palliative care. The Louisville-based health insurer plans to use proceeds for general corporate purposes.

The sale is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Humana stated it does not anticipate a material impact to 2026 earnings from the

Humana to sell minority stake in Gentiva for $900 million

Wed, 10 Jun 2026 16:30:27 -0400

Humana Inc. (NYSE: HUM) signed a definitive agreement to divest its minority interest in Gentiva to a consortium of investors for approximately $900 million, according to a company statement.

Humana Announces Agreement to Divest Minority Interest in Gentiva